StockNews.com Begins Coverage on Zevra Therapeutics (NASDAQ:KMPH)

Stock analysts at StockNews.com initiated coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a research report issued on Friday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Cantor Fitzgerald initiated coverage on shares of Zevra Therapeutics in a report on Thursday, November 17th. They set an “overweight” rating and a $20.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Zevra Therapeutics Price Performance

The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.14. Zevra Therapeutics has a 12 month low of $4.00 and a 12 month high of $6.92. The stock has a 50-day moving average price of $5.37 and a 200-day moving average price of $5.38.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, CEO Richard W. Pascoe acquired 9,500 shares of the business’s stock in a transaction that occurred on Friday, January 13th. The shares were bought at an average cost of $5.44 per share, with a total value of $51,680.00. Following the completion of the acquisition, the chief executive officer now directly owns 19,973 shares in the company, valued at approximately $108,653.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Pensionmark Financial Group LLC grew its holdings in Zevra Therapeutics by 22.5% in the third quarter. Pensionmark Financial Group LLC now owns 16,350 shares of the specialty pharmaceutical company’s stock worth $102,000 after purchasing an additional 3,000 shares during the last quarter. Arete Wealth Advisors LLC grew its holdings in Zevra Therapeutics by 4.7% in the fourth quarter. Arete Wealth Advisors LLC now owns 82,290 shares of the specialty pharmaceutical company’s stock worth $377,711,100,000 after purchasing an additional 3,725 shares during the last quarter. Man Group plc grew its holdings in Zevra Therapeutics by 12.9% in the fourth quarter. Man Group plc now owns 33,046 shares of the specialty pharmaceutical company’s stock worth $152,000 after purchasing an additional 3,768 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Zevra Therapeutics by 28.3% in the first quarter. JPMorgan Chase & Co. now owns 18,095 shares of the specialty pharmaceutical company’s stock worth $91,000 after purchasing an additional 3,990 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Zevra Therapeutics by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 309,842 shares of the specialty pharmaceutical company’s stock worth $1,422,000 after purchasing an additional 5,190 shares during the last quarter. 19.39% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

(Get Rating)

KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.